Cue Biopharma, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cue Biopharma, Inc. on June 26, 2018. The report discloses a corporate governance event regarding the appointment of a new director to the Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
On June 26, 2018, Frederick Driscoll was appointed as a member of the Board of Directors. He will serve as the Chair of the Audit Committee. Mr. Driscoll brings significant experience as a former CFO of Flexion Therapeutics and Novavax, Inc., and former CEO of Genelabs Technologies, Inc. and OXiGENE, Inc.
Compensation and Governance Details
- Annual Compensation: $50,000 cash retainer and an annual stock option award for 8,000 shares.
- Initial Grant: A one-time stock option award for 50,000 shares vesting in eight equal semi-annual installments.
- Other Roles: Mr. Driscoll currently serves on the boards of Abpro Therapeutics, Cellectar Biosciences Inc., MEI Pharma Inc., and NantKwest Inc.
Key Facts for Investor Verification
- Confirmation of Frederick Driscoll's appointment as Board Member and Audit Committee Chair.
- Review of the specific vesting schedule for the 50,000-share initial stock option grant.
- Assessment of potential conflicts of interest given Mr. Driscoll's concurrent board memberships in other biopharmaceutical companies.
- Verification of the Company's Director Compensation Policy to ensure alignment with the disclosed terms.